Update on immunosuppressive therapy.
In this review we summarize selected articles that have been published about immunosuppressive agents in the past year. These studies fall into three major categories: 1) use of pulse cyclophosphamide in autoimmune diseases other than systemic lupus erythematosus; 2) use of newer immunosuppressive agents such as cyclosporine and FK506 in a variety of rheumatic diseases; and 3) toxicity.
Singer
N G
NG
536 RB & C, Division of Pediatric Immunology Allergy and Rheumatology, Cleveland, OH 44106, USA.
McCune
W J
WJ
D000328:Adult; D001171:Arthritis, Juvenile / Q000188:drug therapy; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy; D002648:Child; D017338:Cladribine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy; D006801:Humans; D006886:Hydroxychloroquine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000293:injuries; D008168:Lung / Q000187:drug effects; D055370:Lung Injury; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010390:Pemphigoid, Benign Mucous Membrane / Q000188:drug therapy; D012160:Retina / Q000187:drug effects; D016559:Tacrolimus / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D017338:Cladribine; D006886:Hydroxychloroquine; D013792:Thalidomide; D016572:Cyclosporine; D003520:Cyclophosphamide; D001379:Azathioprine; D016559:Tacrolimus; D008727:Methotrexate